Medifirst Solutions Inc (OTCMKTS:MFST) in a note to shareholders commented on its recent Conference in Morocco, as well as developments regarding its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. A number of healthcare companies in different countries have requested to be distributors for the Company’s laser technology. Upon completion of a successful negotiation, Medifirst hopes to enter into an exclusive distribution agreement for a Morocco-based medical and healthcare distributor in the near future.
Medifirst is pleased to announce that it satisfied all the vendor registration requirements and has received a Client Approved status for the Mayo Clinic. Commented President Bruce J. Schoengood, “We are very pleased with being accepted as a vendor for such a prestigious and leading medical organization.” Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota. It employs more than 4,500 physicians and scientists and 57,100 allied health staff. The practice specializes in treating difficult cases through tertiary care. It spends over $660 million a year on research.
Medifirst Solutions Inc (OTCMKTS:MFST) recently returned from Morocco, Dubai and France where the Company presented its technology to distributors and medical professionals from several countries. Commented President Bruce J. Schoengood, “The response has been overwhelming and we are working diligently to complete our negotiations and additional demonstrations, which involve ongoing meetings in the Mid-East, Africa and Europe. Medifirst would like to thank all the medical professionals we met in Morocco, Dubai and France.”
Find out when $MFST stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Additionally, Medifirst is in final negotiations, which if successful, involve bulk sales, with a London-based entrepreneur for representation in 11 countries to distribute the Time Machine Laser and ongoing negotiating continues with a Saudi-based medical distributor. Medifirst will update shareholders as soon as all negotiations and agreements are completed as to the final results in terms of sales and distribution. Medifirst continues presenting and working with individual practitioners for individual sales overseas and in the US, which efforts are focused on generating short-term revenues and establishing Time Machine ambassadors for longer-term growth. Continued Schoengood, “We know everyone is anxious for sales and great success and we are working as expeditiously as possible to complete all the current deals and continue to expand our sales force and infrastructure for both US and international sales.”
MFST anticipates a shift in its current strategy to increase its product portfolio through upcoming acquisitions. Exclusive licensing deals are very valuable but owning specific intellectual property which include trademarks, patents and all related IP, would provide more security as well as increased value to the Company. The company anticipates a rollout of additional products in 2017.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 – 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, according to the company often gives patients immediate results with no redness, swelling or down-time. This laser offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer.
This is a unique product in an age where traditional opioid based medications used for pain are losing market share to cannabis and other methods to control pain making MFST a good stock to watch in 2017. For continuing coverage on shares of $MFST stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!